Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro
Abstract The treatment of diseases with biologic agents can result in the formation of antidrug antibodies (ADA). Although drivers for ADA formation are unknown, a role for antigen presentation is likely, and variation in human leukocyte antigen (HLA) genes has been shown to be associated with occur...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.13264 |
| _version_ | 1811243208798109696 |
|---|---|
| author | Christian Hammer Jane Ruppel Lynn Kamen Julie Hunkapiller Ira Mellman Valerie Quarmby |
| author_facet | Christian Hammer Jane Ruppel Lynn Kamen Julie Hunkapiller Ira Mellman Valerie Quarmby |
| author_sort | Christian Hammer |
| collection | DOAJ |
| description | Abstract The treatment of diseases with biologic agents can result in the formation of antidrug antibodies (ADA). Although drivers for ADA formation are unknown, a role for antigen presentation is likely, and variation in human leukocyte antigen (HLA) genes has been shown to be associated with occurrence of ADA for several biologics. Here, we performed an HLA‐wide association study in 1982 patients treated with the anti‐PD‐L1 antibody atezolizumab across eight clinical trials. On average, 29.8% of patients were ADA‐positive (N = 591, range of 13.5%–38.4% per study) and 14.6% of patients were positive for ADA that were neutralizing in vitro (neutralizing antibodies [NAb], N = 278, range of 6.4%–21.9% per study). In a meta‐analysis of logistic regression coefficients, we found statistically significant associations between HLA class II alleles and ADA status. The top‐associated alleles were HLA‐DRB1*01:01 in a comparison of ADA‐positive versus ADA‐negative patients (p = 3.4 × 10−5, odds ratio [OR] 1.96, 95% confidence interval [95% CI] 1.64–2.28) and HLA‐DQA1*01:01 when comparing NAb‐positive with ADA‐negative patients (p = 2.8 × 10−7, OR 2.31, 95% CI 1.98–2.66). Both alleles occur together on a common HLA haplotype, and analyses considering only NAb‐negative, ADA‐positive patients did not yield significant results, suggesting that the genetic association is mainly driven by NAb status. In conclusion, our study showed that HLA class II genotype is associated with the risk of developing ADA, and specifically NAb, in patients treated with atezolizumab, but the effect estimates suggest that immunogenetic factors are not sufficient as clinically meaningful predictors. |
| first_indexed | 2024-04-12T14:03:31Z |
| format | Article |
| id | doaj.art-aa305244aea0411dafc2eccf80776734 |
| institution | Directory Open Access Journal |
| issn | 1752-8054 1752-8062 |
| language | English |
| last_indexed | 2024-04-12T14:03:31Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj.art-aa305244aea0411dafc2eccf807767342022-12-22T03:30:09ZengWileyClinical and Translational Science1752-80541752-80622022-06-011561393139910.1111/cts.13264Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitroChristian Hammer0Jane Ruppel1Lynn Kamen2Julie Hunkapiller3Ira Mellman4Valerie Quarmby5Genentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAGenentech, Inc. South San Francisco California USAAbstract The treatment of diseases with biologic agents can result in the formation of antidrug antibodies (ADA). Although drivers for ADA formation are unknown, a role for antigen presentation is likely, and variation in human leukocyte antigen (HLA) genes has been shown to be associated with occurrence of ADA for several biologics. Here, we performed an HLA‐wide association study in 1982 patients treated with the anti‐PD‐L1 antibody atezolizumab across eight clinical trials. On average, 29.8% of patients were ADA‐positive (N = 591, range of 13.5%–38.4% per study) and 14.6% of patients were positive for ADA that were neutralizing in vitro (neutralizing antibodies [NAb], N = 278, range of 6.4%–21.9% per study). In a meta‐analysis of logistic regression coefficients, we found statistically significant associations between HLA class II alleles and ADA status. The top‐associated alleles were HLA‐DRB1*01:01 in a comparison of ADA‐positive versus ADA‐negative patients (p = 3.4 × 10−5, odds ratio [OR] 1.96, 95% confidence interval [95% CI] 1.64–2.28) and HLA‐DQA1*01:01 when comparing NAb‐positive with ADA‐negative patients (p = 2.8 × 10−7, OR 2.31, 95% CI 1.98–2.66). Both alleles occur together on a common HLA haplotype, and analyses considering only NAb‐negative, ADA‐positive patients did not yield significant results, suggesting that the genetic association is mainly driven by NAb status. In conclusion, our study showed that HLA class II genotype is associated with the risk of developing ADA, and specifically NAb, in patients treated with atezolizumab, but the effect estimates suggest that immunogenetic factors are not sufficient as clinically meaningful predictors.https://doi.org/10.1111/cts.13264 |
| spellingShingle | Christian Hammer Jane Ruppel Lynn Kamen Julie Hunkapiller Ira Mellman Valerie Quarmby Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro Clinical and Translational Science |
| title | Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro |
| title_full | Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro |
| title_fullStr | Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro |
| title_full_unstemmed | Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro |
| title_short | Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro |
| title_sort | allelic variation in hla drb1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro |
| url | https://doi.org/10.1111/cts.13264 |
| work_keys_str_mv | AT christianhammer allelicvariationinhladrb1isassociatedwithdevelopmentofantidrugantibodiesincancerpatientstreatedwithatezolizumabthatareneutralizinginvitro AT janeruppel allelicvariationinhladrb1isassociatedwithdevelopmentofantidrugantibodiesincancerpatientstreatedwithatezolizumabthatareneutralizinginvitro AT lynnkamen allelicvariationinhladrb1isassociatedwithdevelopmentofantidrugantibodiesincancerpatientstreatedwithatezolizumabthatareneutralizinginvitro AT juliehunkapiller allelicvariationinhladrb1isassociatedwithdevelopmentofantidrugantibodiesincancerpatientstreatedwithatezolizumabthatareneutralizinginvitro AT iramellman allelicvariationinhladrb1isassociatedwithdevelopmentofantidrugantibodiesincancerpatientstreatedwithatezolizumabthatareneutralizinginvitro AT valeriequarmby allelicvariationinhladrb1isassociatedwithdevelopmentofantidrugantibodiesincancerpatientstreatedwithatezolizumabthatareneutralizinginvitro |